Literature DB >> 30592074

Voxelotor treatment of a patient with sickle cell disease and very severe anemia.

Arun S Shet1, Laurel Mendelsohn1, Julia Harper2, David Ostrowski2, Eric R Henry2, Eveline Gwaabe1, Jim Nichols1, Abdu I Alayash3, William A Eaton2, Swee Lay Thein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30592074      PMCID： PMC6408257          DOI： 10.1002/ajh.25389

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  5 in total

Review 1.  Treating sickle cell disease by targeting HbS polymerization.

Authors:  William A Eaton; H Franklin Bunn
Journal:  Blood       Date:  2017-04-06       Impact factor: 22.113

2.  Case series of patients with severe sickle cell disease treated with voxelotor (GBT440) by compassionate access.

Authors:  Gershwin Blyden; Kenneth R Bridges; Lanetta Bronte
Journal:  Am J Hematol       Date:  2018-05-12       Impact factor: 10.047

3.  Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review.

Authors:  Jane A Little; Vicki R McGowan; Gregory J Kato; Kristine S Partovi; Jordan J Feld; Irina Maric; Sabrina Martyr; James G Taylor; Roberto F Machado; Theo Heller; Oswaldo Castro; Mark T Gladwin
Journal:  Haematologica       Date:  2006-08       Impact factor: 9.941

4.  Voxelotor (GBT440) produces interference in measurements of hemoglobin S.

Authors:  Nicola J Rutherford; Katie L Thoren; Zahra Shajani-Yi; Jennifer M Colby
Journal:  Clin Chim Acta       Date:  2018-03-27       Impact factor: 3.786

5.  Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin.

Authors:  Brian Metcalf; Chihyuan Chuang; Kobina Dufu; Mira P Patel; Abel Silva-Garcia; Carl Johnson; Qing Lu; James R Partridge; Larysa Patskovska; Yury Patskovsky; Steven C Almo; Matthew P Jacobson; Lan Hua; Qing Xu; Stephen L Gwaltney; Calvin Yee; Jason Harris; Bradley P Morgan; Joyce James; Donghong Xu; Athiwat Hutchaleelaha; Kumar Paulvannan; Donna Oksenberg; Zhe Li
Journal:  ACS Med Chem Lett       Date:  2017-01-23       Impact factor: 4.345
  5 in total
  3 in total

Review 1.  Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.

Authors:  Maurice H Dick; Arowa Abdelgadir; Vaishnavi Vijaya Kulkarni; Hamna Akram; Abanti Chatterjee; Sushil Pokhrel; Safeera Khan
Journal:  Cureus       Date:  2022-05-11

2.  Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.

Authors:  Eric R Henry; Belhu Metaferia; Quan Li; Julia Harper; Robert B Best; Kristen E Glass; Troy Cellmer; Emily B Dunkelberger; Anna Conrey; Swee Lay Thein; H Franklin Bunn; William A Eaton
Journal:  Blood       Date:  2021-09-30       Impact factor: 25.476

3.  MWC allosteric model explains unusual hemoglobin-oxygen binding curves from sickle cell drug binding.

Authors:  Eric R Henry; Julia Harper; Kristen E Glass; Belhu Metaferia; John M Louis; William A Eaton
Journal:  Biophys J       Date:  2021-04-29       Impact factor: 3.699
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.